Inhibition of indoleamine 2,3-dioxygenase, and immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy (Nature Medicine, 11:312-319, March 2005)

報告日期: 2005/09/23
報告時間: 17:10/18:00
報告學生: 王怡文
講評老師: 賴明德
附件下載:

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

                             

Time: 9/23/2005 17:10-18:00

Place: Room 602            

Speaker: 王怡文 

Commentator: 賴明德

Immune escape is a central hallmark of cancer, but compared to other recognized hallmark of cancer-suppressor loss, invasion and metastasis- much less is know about the genetic of immune escape. The basis before studies, Bin1 is an MYC-interacting protein with features of a tumor suppressor, and it is involved in controlling expression of the Indo gene, which encodes the IDO enzyme. In this study, using a mouse knockout model, indicate that Bin1 can restrain immune escape of oncogenically transformed cells from T cell-dependent immunity by influences the STAT1- and NF-kB dependent expression of IDO. IDO is an immunoregulator enzyme and that can catalyze the initial and rate-limiting step in the catabolism of tryptophan. In the meantime, use an established breast cancer model, in MMTV-Neu mice, combines the small-molecule inhibitor of IDO and cytotoxic chemotherapy, create a cure to the processings cancer is the more efficient strategy.

References:

1.      Uyttenhove, C. et al. Nat Med. 2003 Oct ; 9(10):1269-74.

2.      Muller, A.J. et al. Mol Cell Biol. 2003 Jun ; 23(12):4295-4306.

3.      Elliott, K. et al. Oncogene. 1999 Jun 17;18(24):3564-73.